Plasma endothelin in congestive heart failure: A predictor of cardiac death?

• Published in: Journal of cardiac failure Vol. 2; no. 2; pp. 71 - 76
• Main Authors: Galatius-Jensen, Søren, Wroblewski, Henrik, Emmeluth, Claus, Bie, Peter, Haunsø, Stig, Kastrup, Jens
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.1996
• Subjects: Adult; Aged; Biomarkers - blood; Endothelins - blood; Female; Follow-Up Studies; heart disease; Heart Failure - blood; Heart Failure - mortality; Humans; Male; Middle Aged; peptides; Prognosis; Prospective Studies; Survival Rate; peptides; prognosis; heart disease
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1016/S1071-9164(96)80025-X

Endothelin is a potent vasoconstrictor, with growth-promoting and possible cardiotoxic and arrhythmogenic properties. This study investigates the association between increased plasma endothelin in congestive heart failure and prognosis. Forty-four patients with congestive heart failure showed increasedplasma endothelin concentrations (mean ± SD, 3.7 ± 1.7 pg/mL; n = 44) compared with healthy volunteers (2.0 ± 0.4 pg/mL, n = 21, P < .00003). Plasma endothelin increased with the severity of the disease. All patients were followed for an average of 17 months (range, 2–25 months). Cardiac mortality was 27% (8 of 30 patients) in the group with plasma endothelin concentrations above 3 pg/mL and 0% (0 of 14 patients) in the group with plasma endothelin concentrations below 3 pg/mL ( P < .05). In contrast, separation of patients based on different New York Heart Association groups and ejection fractions revealed no significant difference regarding this endpoint. Increased plasma endothelin concentrations in patients with congestive heartfailure appears to serve as a predictor of cardiac death.